Cancer Research Horizons rewards innovation and entrepreneurship
Cancer Research Horizons, the innovation arm of Cancer Research UK, announced the winners of its third Innovation and Entrepreneurship Awards during an awards ceremony at Merchant Taylors’ Hall, London.
Dr Alessia Errico, Associate Director of Search and Evaluation at Cancer Research Horizons, said: “These remarkable innovators demonstrate the determination and collaborative spirit essential to transform scientific discoveries into real-world solutions. Their entrepreneurial leadership and drive shows what’s possible when excellence meets bold thinking, inspiring us all to accelerate progress and bring tangible benefit to people affected by cancer.”
The winners are:
- Early Career Entrepreneur of the Year: Jessica Corry, CEO and co-founder of Xterna, which is developing enhanced nucleic acids to target specific cell types. She was previously a postdoctoral fellow in the Applied Biotechnology Lab at the Francis Crick Institute.
- Entrepreneurial Group Leader of the Year: Tim Witney, who leads the Witney Lab at King’s College London, which is pioneering radionuclide-based imaging agents that target intracellular biomarkers overexpressed in cancer.
- Woman Entrepreneur of the Year (sponsored by Mewburn Ellis): Natalie Mount, CEO of Cytospire Therapeutics, which is advancing a portfolio of next-generation immune cell engagers. She is also a venture partner at Abingworth and previously led Adaptate Biotherapeutics from its inception to its successful acquisition by Takeda Pharmaceuticals.
- New Start-Up of the Year: Trogenix – a University of Edinburgh spinout building a precision viral immunotherapy platform to treat aggressive cancers. Emerging from stealth mode in 2024, it has already shown promising preclinical results for its lead programme targeting glioblastoma.
- Further, Faster, Together (Industry-Academia Collaboration): Cambridge Children’s Hospital Innovation Hub – a collaboration between Cambridge University Hospitals and Illumina to accelerate genomic diagnostics for children. By enabling rapid whole-genome sequencing and translational research, the team aims to better understand how diseases develop in childhood.
Special recognition awards
Several special awards recognised contributions to the academic cancer entrepreneurial field.
- Entrepreneurship Recognition Award: Peter Parker – internationally recognised for groundbreaking research on protein kinase C and related signalling pathways that underpin modern targeted cancer therapies. A prolific entrepreneur and mentor, he has founded multiple biotech companies, including PIramed, Symansis and FASTBASE Solutions, and held leadership roles across the Crick, MRC, and King’s College London, driving innovation from discovery to patient impact.
- Horizon Explorer Recognition Award: eDyNAmiC, the Cancer Grand Challenges team recognised for their groundbreaking research redefining our understanding of extrachromosomal DNA (ecDNA) in cancer. Led by Professor Paul Mischel at Stanford, their work has revealed how ecDNA drives tumour evolution and resistance, culminating in a trio of landmark Nature papers.
- Start-Up Achievement Recognition Award: Myricx Bio. Founded by Ed Tate, Roberto Solari and Andrew Bell at Imperial College London, Myricx Bio develops novel antibody drug conjugates using its proprietary NMT inhibitor payload platform to target treatment-resistant cancers. In 2024, the company raised £90m in one of Europe’s largest Series A funding rounds to advance its pipeline into the clinic.
Diana Turner, Senior Digital Content Editor, DDW
